四三肽
化学
重新调整用途
MAPK/ERK通路
药理学
冈田酸
磷酸酶
激酶
对接(动物)
磷酸化
生物化学
法尼酰转移酶
蛋白磷酸酶2
蛋白激酶A
突变体
克拉斯
可药性
药物重新定位
药物发现
绑定域
作者
Yanyi He,Jinying Gu,Liwen Hua,Daichao Zhai,Qifei Huang,Jiayue Pei,Qidong You,Qiuyue Zhang,Lei Wang
标识
DOI:10.1021/acsmedchemlett.6c00068
摘要
Small-molecule modulators targeting the N-terminal tetratricopeptide repeat (TPR) domain of protein phosphatase 5 (PP5) remain largely unexplored. Here, we report the repurposing of ilaprazole as a PP5 TPR domain binder identified via a fluorescence polarization-based competitive screen. Biophysical assays and molecular docking supported the interaction within the PP5 TPR binding pocket, revealing key structural features distinguishing ilaprazole from related proton pump inhibitors. In KRAS mutant colorectal cancer cells, ilaprazole engaged cellular PP5, leading to reduced RAF stability and suppressed mitogen-activated protein kinase (MAPK) signaling. While exhibiting minimal single-agent effects, ilaprazole sensitized cells to the MEK inhibitor binimetinib. These results validate the PP5 TPR domain as a druggable site and establish ilaprazole as a lead scaffold for pharmacological modulation of PP5-associated MAPK signaling.
科研通智能强力驱动
Strongly Powered by AbleSci AI